Cyberknife stereotactic radiosurgery for brain metastases

The introduction of hypofractionated stereotactic radiosurgery (hSRS) has expanded the spectrum of treatment options beyond the established single-fraction stereotactic radiosurgery and fractionated radiotherapy. A team of researchers from Germany has provided insights into the efficacy and side effects of hSRS using Cyberknife in treating patients with challenging brain metastases (BM) and a poor prognosis. Their analysis, encompassing 34 patients with a total of 75 BM, revealed that 53% of the cases involved large tumors. The study included all patients who underwent CK-hSRS over a span of 3 years, analyzed retrospectively. The radiation regimen demonstrated notable effectiveness and tolerability, positioning Cyberknife as a promising salvage treatment for critical BM in individuals with a very poor prognosis and clinical performance status. By bridging the gap between surgical interventions, stereotactic radiosurgery, conventional radiotherapy, and palliative care, CK-hSRS emerges as a valuable addition to the treatment armamentarium.